Clinical trials: Ebola Hemorrhagic Fever
Ebola Virus Disease
PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Background: Genes are instructions that tell the body how to work and grow. They can affect how the body responds to infection. Researchers want to learn more about genes that affect how the body responds to the Ebola virus.
- Trial name
- NCT03098862
- Where
- 4 sites in Liberia
- Volunteers
- 4,830 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola
A Study of a New Vaccine Against Two Types of Ebola
An open-label, non-randomised, dose escalation, first-in-human, single centre, phase I clinical trial to determine the safety and immunogenicity of a bivalent ChAdOx1 vectored vaccine against Zaire and Sudan Ebola virus species…
- Trial name
- NCT05079750
- Testing
- ChAdOx1 biEBOV
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Virus Infection
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single ascending dose (SAD) study followed by a multiple-dose cohort in healthy male and female subjects.
- Trial name
- NCT02041715
- Testing
- TKM-100802 for Injection
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Ebola Virus Disease
Evaluation of the FilmArray BioThreat-E Test
The aim of our study is to assess the analytical and clinical performance of the FilmArray (FA) BioThreat-E test (BioFire®) for the diagnosis of Ebola virus disease in the field in Guinea versus conventional molecular techniques.
- Trial name
- NCT02658331
- Volunteers
- 156 people
- Sponsor
- BioMérieux
Ebola Virus Disease, Hemorrhagic Fever
Phase 1 Trial of Ebola Vaccine in Mali
Ebola virus causes an infection known as Ebola virus disease (EVD). This is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02267109
- Testing
- Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z
- Where
- Mali
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Ebola Virus Disease
Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination
This is a clinical trial in which healthy volunteers will be administered two experimental Ebola vaccines: ChAd3-EBO Z and MVA-EBO Z.
- Trial name
- NCT02485912
- Testing
- ChAd3-EBO Z, MVA-EBO Z
- Where
- Senegal
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Acute Ebola Virus Disease
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
The objective of this Phase 1 safety study is to provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV.
- Trial name
- NCT02295501
- Testing
- INTERCEPT Plasma
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cerus Corporation
Ebola Vaccine
Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be well tolerated and immunogenic.
- Trial name
- NCT02464670
- Testing
- INO-4201, INO-4202, INO-4212
- Where
- 3 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Ebola Virus Disease
Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III
Background: Ebola virus disease (EVD) is a viral fever that can cause internal bleeding. The death rate from EVD is very high. In a 2014 outbreak in West Africa, 28,000 were affected and 11,000 died.
- Trial name
- NCT05494801
- Where
- Liberia
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein
The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of two doses of the HPIV3/ΔHNF/EbovZ GP vaccine candidate when administered intranasally in healthy adults.
- Trial name
- NCT03462004
- Testing
- HPIV3/ΔHNF/EbovZ GP vaccine
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hemorrhagic Fever, Ebola
Open Study of the Duration of Immunity After Vaccination With GamEvac
The purpose of this study is to evaluate the post-vaccination immune status at different time points in subjects immunized against Ebola Virus Disease; to select an optimal regimen of product administration; and, to assess safety…
- Trial name
- NCT02911428
- Testing
- blood sampling collection
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Healthy Adult Immune Responses to Vaccine
Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults
Background: Ebola virus causes an infection known as Ebola virus disease (EVD). This it is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02231866
- Testing
- VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP
- Where
- 3 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola
The purpose of this study is to determine how safe and tolerable Brincidofovir (BCV) is when given for post exposure prophylaxis of Ebola virus disease.
- Trial name
- BCV EBOV (NCT04268966)
- Testing
- Brincidofovir
- Sponsor
- Jazz Pharmaceuticals
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469
- Trial name
- NCT07737717
- Testing
- mRNA-1469
- Where
- 3 sites in Canada
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Ebola Virus Disease
A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z
This is a clinical trial in which healthy volunteers will be administered experimental Ebola vaccines. The investigators will vaccinate four groups of volunteers.
- Trial name
- NCT02451891
- Testing
- MVA-EBO Z, ChAd3-EBO Z
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Virus Disease
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
- Trial name
- NCT03576690
- Testing
- REGN3470-3471-3479
- Sponsor
- Regeneron Pharmaceuticals
Ebola Vaccine
Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure
This study is a multi-center, open label, randomized phase 3b trial to assess the durability of Immunity induced by the Ebolavirus Vaccine VSV-EBOV ( with or without booster vaccination) in individuals at potential occupational…
- Trial name
- PREPARE (NCT05959421)
- Testing
- ERVEBO® (rVSV∆G-ZEBOV-GP)
- Where
- 2 sites in Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Ebola
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices.
- Trial name
- NCT03031912
- Testing
- V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine, Saline
- Where
- Canada
- Volunteers
- 251 people
- Sponsor
- Canadian Immunization Research Network
Ebola Vaccines, Marburg Virus Disease
Ebola and Marburg Virus Vaccines
This study will determine if experimental vaccines to prevent Ebola virus infection and Marburg virus infection are safe and what side effects, if any, they cause.
- Conditions
- Ebola Vaccines, Marburg Virus Disease, Ebola Virus Disease, Marburgvirus
- Trial name
- NCT00605514
- Testing
- VRC-EBODNA023-00-VP, VRC-MARDNA025-00-VP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon
LA rVSVΔG-ZEBOV-GP -02-PED is a Phase 1/2, randomized, controlled open label trial. The LA rVSVΔG-ZEBOV-GP -02-PED trial aims primarily to assess the clinical significance of shedding of the rVSV RNA following vaccination with…
- Trial name
- EBOLAPED (NCT05130398)
- Testing
- rVSVΔG-ZEBOV-GP, V920, Fibre and equilibrate breakfast and lunch, Active detection and treatment of pathogens
- Where
- Gabon
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné